by McKesson Ventures | May 13, 2019 | Portfolio News
Liquid biopsy company GRAIL announced today that its multi-cancer test has been granted Breakthrough Device designation from the U.S. Food and Drug Administration. This investigational blood test is in development for the early detection of multiple cancer types in...
by McKesson Ventures | May 2, 2019 | Portfolio News
Kyruus recently announced that its ProviderMatch DirectBook has been included in the Cerner App Gallery. Cerner, an electronic health record platform, is used by hospitals across the U.S. The inclusion in the Cerner App Gallery means that ProviderMatch DirectBook has...
by McKesson Ventures | Apr 26, 2019 | Portfolio News
Retail electronics chain Best Buy recently announced a new partnership with Israeli health tech company TytoCare to carry the company’s digital diagnostics kit. The kits will be available at Best Buy stores in California, North and South Dakota, Ohio, and Minnesota,...
by McKesson Ventures | Apr 26, 2019 | Portfolio News
Provider groups and healthcare executives are on board with Medicare’s new Primary Cares Initiative, which will shift primary care from fee-for-service to value-based reimbursement models starting in 2020. “Providing adequate financial support for high quality primary...
by McKesson Ventures | Apr 22, 2019 | Portfolio News
AllyAlign Health, an administrator of Medicare Advantage special needs plans that benefit long-term care providers, announced today that it had closed a $10 million strategic funding round led by McKesson Ventures. Existing investors Heritage Healthcare Innovation...
by McKesson Ventures | Apr 12, 2019 | Portfolio News
The FDA, Brigham and Women’s Hospital, and Aetion are expanding their real-world evidence (RWE) demonstration to predict the results of seven ongoing FDA drug trials. The FDA drug or treatment trials are in Phase IV, meaning the drug or treatment is being tracked over...
